- A + A KUALA LUMPUR (Jan 20): Clean energy specialist Solarvest Holdings Bhd, insurers QBE Insurance (Malaysia) Bhd and Anora Agency Sdn Bhd collaborate to provide solar photovoltaic (PV) investors a solar investment insurance product, namely the SolarPro Line-Stoppage insurance policy. In a joint statement on Thursday (Jan 20), the trio said they signed a tripartite memorandum of understanding (MoU) to enable Solarvest to be able to take up, as well as provide its solar PV investors with an all-new solar investment insurance product. The solar investment insurance product, namely the SolarPro Line-Stoppage insurance policy, is a comprehensive general liability policy with consequential loss underwritten by QBE Malaysia, through Anora. According to the three companies, this insurance product is aimed to offer solar PV investors better coverage to ensure business continuity and peace of mind. Solarvest executive director and chief executive officer (CEO) Davis … [Read more...] about Solarvest, QBE Malaysia, Anora collaborate to offer solar investment insurance product
Health and dental insurance companies
Welcome to the Inc. Founders Project podcast--where we tell tales about the guts, inspiration, and drive of the people and companies building the future. Each week, we dig into a founder's professional playbook--and uncover what makes them tick. On this week's episode: How to Build From the Ground Up With Eren Bali of Carbon Health To build one successful startup is no easy feat, but to do it twice is even more impressive. Eren Bali launched his first project, Udemy, to make education more accessible, and scaled the company to reach more than 10 million students worldwide. In 2016, Bali started Carbon Health to reimagine the health care experience from the ground up. He's raised over $500 million in venture funding and plans to open 1,500 clinics across the country over the next few years. Eren shares why he believes the future involves "omnichannel health care," how Covid went from a business threat to a major accelerant, and why he doubled down on communication skills in … [Read more...] about Health Care Needs an Upgrade–This Founder Is Here to Deliver
Since the stock market bottomed out in March 2020, investors have enjoyed historic gains. It took less than 17 months for the broad-based S&P 500 to double from its bear market low. Furthermore, the widely followed index came close to tripling its long-term average annual return in 2021. Despite this incredible outperformance, amazing deals remain. Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. If you have cash ready to invest and are willing to let time be your ally, the following four stocks all have the tools to turn $100,000 into $1 million by 2030. Image source: Getty Images. Teladoc Health There's no sugarcoating it: telehealth giant Teladoc Health ( NYSE:TDOC ) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its … [Read more...] about 4 Stocks That Can Turn $100,000 Into $1 Million by 2030
Share to Twitter Share to Linkedin Enigma’s cofounders: Marc DaCosta (left) is chairman; Hicham Oudghiri (right) is CEO. Jamel Toppin for Forbes There’s a fintech revolution going on inside Wall Street’s biggest firms. At asset management giants from Blackrock to Third Point, banks such as Goldman Sachs and Citigroup, and financial service behemoths Nasdaq, MetLife and American Express, upstart fintech firms are revolutionizing the way they operate. These blue-chip institutions are both users and investors in the most disruptive fintech firms on Wall Street, as laid out in Forbes’ 2019 Fintech 50. Pioneering fintechs are allowing banks to make faster and better underwriting decisions, and to get a better handle on their risk. Armed with powerful new sets of data and machine-learning algorithms, banks and insurers are now able to sift through haystacks of information to quickly spot financial fraud, identity theft and those who are trying to … [Read more...] about The Future Of Wall Street: Fintech 50 2019
Late last December, Amgen ( NASDAQ:AMGN ) announced that the U.S. Food and Drug Administration (FDA) had expanded Otezla's approval from moderate to severe plaque psoriasis to include mild to moderate cases. What prompted the FDA to expand Otezla's plaque psoriasis indication? And what will this label expansion contribute to the pharma company's revenue? Let's dive into Otezla's phase 3 clinical trial results and its potential addressable market to answer these questions. Image source: Getty Images. The first and only oral therapy for all severities Paraphrasing Healthline, plaque psoriasis is a chronic condition that results in red and itchy skin due to the body producing new skin cells too quickly. The severity of plaque psoriasis is determined by how much of the body's surface area is affected by the disease. Mildly severe cases of the condition cover less than 3% of the body's surface area. Moderate occurrence of the disease is considered as affecting between … [Read more...] about What Does This Label Expansion Mean for Amgen’s Shareholders?
Share to Twitter Share to Linkedin Almost every personal finance company on Forbes’ 2019 Fintech 50 list is betting on the insights of behavioral finance to take their company to the next level. List returnees Lemonade and Acorns have been doing this successfully for years. Our three newcomers on the list (Chime, Even and Root Insurance) are doing this with the goal of helping the under-served save more. And all of them allow you to save, invest or insure conveniently and quickly from your cellphone. Here are seven of the country’s most promising personal finance and insurance companies: CEO of Acorns Noah Kerner speaks during the 2018 Yahoo Finance All Markets Summit at The Times ... [+] Center on September 20, 2018, in New York City. (Photo by John Lamparski/Getty Images) Getty Acorns Irvine, California For $1 a month, the micro-investing mobile app rounds up each debit or credit card purchase to nearest dollar, investing extra … [Read more...] about The Future Of Personal Finance: Fintech 50 2019
The idea of buying Teladoc Health ( NYSE:TDOC ) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn't off to a brilliant start, either. The shares have lost about 14% since Dec. 31. Investors are worrying that patients may abandon telemedicine after the pandemic ends. And that would mean Teladoc's best days are behind it. If that's the case, how will the still-unprofitable company make it to profitability? These are risks. But I also see some clues indicating these risks may not take shape. In fact, there are three great reasons to buy shares of Teladoc right now. Image source: Getty Images. 1. It's more than just a COVID stock Some investors viewed Teladoc as a "coronavirus stock" because patients flocked to online medical appointments -- instead of in-person ones -- during the early days of the health crisis. And those investors were right. The pandemic gave Teladoc the opportunity to attract more … [Read more...] about 3 Reasons to Buy Teladoc in 2022
The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate. Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason. 1. Amgen Biotech company Amgen ( NASDAQ:AMGN ) has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more. Image source: Getty Images. When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A … [Read more...] about Is It Time to Buy the Dow’s 3 Worst Performing Stocks This Year?
As we begin 2022, many companies are still being impacted by the effects of the pandemic. At the top of that list is Teladoc Health ( NYSE:TDOC ) , the telehealth company that saw its usage and stock price surge during the height of the pandemic as patients needing medical care turned to its platform to see doctors virtually. Considering this backdrop, investors could expect to see Teladoc's results tapering off, fitting the company neatly into the pandemic stock narrative. However, the actual results over the past few quarters tell a different story. So should investors buy, sell, or hold Teladoc in 2022? Let's take a look. Image source: Getty Images. Continued strong growth In the third quarter of 2021, Teladoc reported year-over-year revenue growth of 81%, continuing a streak of sequential revenue growth since the beginning of 2019. On its own, the 81% revenue growth is excellent, but it's even more impressive considering that Q3 of 2020 featured growth of … [Read more...] about Teladoc Stock: Buy, Sell or Hold In 2022?
Stocks rarely go straight up. When they do, the uncommon occurrence is called a "parabolic move." In stock terminology, such as move is defined by a sudden and dramatic increase in buying volume, thereby causing the company's share price to rapidly rise in a manner that resembles a parabola. Oddly enough, this phenomenon has happened on a far more regular basis in 2021 than at any other time in the history of the U.S. stock market. The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition ( NASDAQ:DWAC ) and Phunware ( NASDAQ:PHUN ) . Last week, Digital World Acquisition's shares rose by as much as 1,500%. Phunware's shares, for their part, posted a jaw-dropping intraday high of over 2,000% during a single trading session last week. This week, it might be biotech 's turn at the parabolic-move game. Shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) and Ocugen ( NASDAQ:OCGN … [Read more...] about 2 Biotech Stocks That Could Go Parabolic This Week